[Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication].
We evaluated the renoprotective effects of adding aliskiren to treatment with losartan in hypertensive patients with type 2 diabetes and nephropathy. A total of 599 patients were randomized to six months of treatment with placebo or aliskiren in addition to losartan 100 mg and optimal antihypertensive therapy. The primary outcome was a reduction in the urinary albumin-creatinine ratio. Aliskiren 300 mg daily reduced the mean urinary albumin-creatinine ratio by 20% (p < 0.001) compared with placebo. The number of adverse events was similar between groups. Aliskiren is renoprotective independently of its blood pressure lowering effect.
Parving
Hans-Henrik
HH
Aarhus Universitet, Det Sundhedsvidenskabelige Fakultet, Steno Diabetes Center. hhparving@dadlnet.dk
Persson
Frederik
F
Lewis
Julia B
JB
Lewis
Edmund J
EJ
Hollenberg
Norman K
NK